Shareholder Wei Xuening of Changchun Bcht Biotechnology Co., Ltd. (688276.SH) has reduced his holding by a total of 301,800 shares in the company.
Baike Biological (688276.SH) issued a statement on January 15, 2025, stating that the company has received a letter from shareholder Wei Xueling...
Changchun Bcht Biotechnology (688276.SH) announced that on January 15, 2025, the company received a notice from shareholder Mr. Wei Xuening regarding the implementation results of the reduction plan. The reduction results are as follows: Mr. Wei Xuening reduced his holdings in the company by a total of 301,800 shares through centralized bidding trading, accounting for 0.0730% of the total share capital of the company. As of the disclosure date of this announcement, the time period for this reduction plan has been completed.
Related Articles
HK Stock Market Move | ALEBUND-B(09637) rose nearly 4% at one point during intraday trading, with an amplitude of 13.53%. Hong Kong-listed innovative drug stocks strengthened collectively. AP308, a new drug for the treatment of IgA nephropathy, received approval from the U.S. FDA for clinical trials.
BUTONG GROUP (06090) repurchased 110,000 shares for HK$3.8656 million on October 15.
LEADS BIOLABS-B(09887): First Patient Dosed in Phase IB/II Clinical Trial of Vilixin (Opatilimab, PD-L1/41BB Bispecific Antibody) in Combination Therapy for Metastatic Colorectal Cancer
HK Stock Market Move | ALEBUND-B(09637) rose nearly 4% at one point during intraday trading, with an amplitude of 13.53%. Hong Kong-listed innovative drug stocks strengthened collectively. AP308, a new drug for the treatment of IgA nephropathy, received approval from the U.S. FDA for clinical trials.
BUTONG GROUP (06090) repurchased 110,000 shares for HK$3.8656 million on October 15.
LEADS BIOLABS-B(09887): First Patient Dosed in Phase IB/II Clinical Trial of Vilixin (Opatilimab, PD-L1/41BB Bispecific Antibody) in Combination Therapy for Metastatic Colorectal Cancer
